Merge branch 'main' into extract/2026-03-21-obbba-rht-50b-rural-counterbalance-state-work-requirements
This commit is contained in:
commit
b2f14c9975
10 changed files with 298 additions and 2 deletions
|
|
@ -138,6 +138,12 @@ India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% pr
|
|||
|
||||
Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on March 20, 2026, the day the patent expired. This is 90% below innovator pricing and 2-3x lower than analyst projections made days earlier ($40-77/month within a year). 50+ manufacturers from 40+ companies are entering the market, with Sun Pharma, Zydus, Dr. Reddy's, and Eris launching on Day 1. The 'inflationary through 2035' timeline is empirically wrong for international markets—price compression is happening in 2026, not 2030+.
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-21-semaglutide-us-import-wall-gray-market-pressure]] | Added: 2026-03-21*
|
||||
|
||||
US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale.
|
||||
|
||||
|
||||
|
||||
Relevant Notes:
|
||||
- [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] -- GLP-1s are the largest single contributor to the inflationary cost trajectory
|
||||
|
|
|
|||
|
|
@ -31,6 +31,12 @@ OpenEvidence reached 1 million clinical consultations in a single 24-hour period
|
|||
|
||||
---
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap]] | Added: 2026-03-21*
|
||||
|
||||
OpenEvidence reached 30M+ monthly consultations by March 2026, including a historic milestone of 1 million consultations in a single day on March 10, 2026. The company projects 'more than 100 million Americans will be treated by a clinician using OpenEvidence this year.' This represents continued exponential growth from the 18M monthly consultations reported in December 2025.
|
||||
|
||||
|
||||
Relevant Notes:
|
||||
- [[centaur team performance depends on role complementarity not mere human-AI combination]] -- OpenEvidence is the clinical centaur: AI provides evidence synthesis, physician provides judgment
|
||||
- [[knowledge scaling bottlenecks kill revolutionary ideas before they reach critical mass]] -- OpenEvidence solved clinical knowledge scaling by making evidence retrieval instant
|
||||
|
|
|
|||
|
|
@ -33,6 +33,12 @@ OpenEvidence valuation trajectory demonstrates winner-take-most dynamics: $3.5B
|
|||
|
||||
---
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap]] | Added: 2026-03-21*
|
||||
|
||||
OpenEvidence raised $250M at $12B valuation in January 2026, representing a 3.4x valuation increase in approximately 3 months (from $3.5B in October 2025). This is extraordinary velocity even by AI standards, with the company achieving $150M ARR (1,803% YoY growth from $7.9M in 2024) at ~90% gross margins. The winner-take-most pattern is evident as OE captures the clinical AI category.
|
||||
|
||||
|
||||
Relevant Notes:
|
||||
- [[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]] -- the category-defining company in healthcare AI clinical workflows, $12B valuation
|
||||
- [[ambient AI documentation reduces physician documentation burden by 73 percent but the relationship between automation and burnout is more complex than time savings alone]] -- Abridge at $5.3B represents the ambient documentation category winner
|
||||
|
|
|
|||
|
|
@ -25,6 +25,12 @@ OpenEvidence achieved 100% USMLE score (first AI in history) and is now deployed
|
|||
|
||||
---
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap]] | Added: 2026-03-21*
|
||||
|
||||
OpenEvidence's medRxiv preprint (November 2025) showed 24% accuracy for relevant answers on complex open-ended clinical scenarios, despite achieving 100% on USMLE-type multiple choice questions. This 76-percentage-point gap between benchmark performance and open-ended clinical scenarios confirms that structured test performance does not predict real-world clinical utility.
|
||||
|
||||
|
||||
Relevant Notes:
|
||||
- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]] -- Stanford/Harvard study shows physician overrides degrade AI performance from 90% to 68%
|
||||
- [[centaur team performance depends on role complementarity not mere human-AI combination]] -- the chess centaur model does NOT generalize cleanly to clinical medicine; interaction design matters
|
||||
|
|
|
|||
|
|
@ -0,0 +1,98 @@
|
|||
---
|
||||
type: source
|
||||
title: "OpenEvidence Raises $250M at $12B Valuation While First Prospective Safety Trial (NCT07199231) Remains Unpublished"
|
||||
author: "BusinessWire / MobiHealthNews / PubMed / ClinicalTrials.gov / STAT News"
|
||||
url: https://www.businesswire.com/news/home/20260121029132/en/OpenEvidence-Raises-$250-Million-to-Build-Medical-Superintelligence-for-Doctors
|
||||
date: 2026-01-21
|
||||
domain: health
|
||||
secondary_domains: [ai-alignment]
|
||||
format: article
|
||||
status: processed
|
||||
priority: high
|
||||
tags: [openevidence, clinical-ai, outcomes-gap, deskilling, automation-bias, valuation, nct07199231, verification-bandwidth, medical-superintelligence]
|
||||
flagged_for_theseus: ["$12B clinical AI valuation with zero outcomes evidence — directly relevant to AI safety at scale; prospective trial NCT07199231 is the first real-world test of clinical AI safety methodology; 'reinforces plans' finding from PMC study could be a Goodhart's Law failure mode"]
|
||||
---
|
||||
|
||||
## Content
|
||||
|
||||
**Series D funding (January 21, 2026):**
|
||||
- Amount: $250 million
|
||||
- Valuation: $12 billion (co-led by Thrive Capital and DST Global)
|
||||
- Previous valuation: $3.5 billion (October 2025 Series C)
|
||||
- Valuation change: 3.4x in approximately 3 months
|
||||
- Total funding: ~$700 million
|
||||
- Revenue: $150M ARR in 2025, up 1,803% YoY from $7.9M in 2024
|
||||
- Gross margins: ~90%
|
||||
- Company's stated goal: "Build Medical Superintelligence for Doctors"
|
||||
|
||||
**Scale metrics (as of March 2026):**
|
||||
- 18M monthly consultations (December 2025) → 30M+ monthly (March 2026)
|
||||
- March 10, 2026: 1 million consultations in a single day (historic milestone)
|
||||
- Active in 10,000+ hospitals and medical centers
|
||||
- Used daily by 40%+ of US physicians
|
||||
- "More than 100 million Americans will be treated by a clinician using OpenEvidence this year"
|
||||
|
||||
**Evidence base — what exists:**
|
||||
|
||||
*Published studies:*
|
||||
1. PMC study (PubMed 40238861, April 2025): Evaluated OE for 5 common chronic conditions (hypertension, hyperlipidemia, DM2, depression, obesity) in primary care. Finding: "impact on clinical decision-making was MINIMAL despite high scores for clarity, relevance, and satisfaction — it reinforced plans rather than modifying them." This is the only published peer-reviewed clinical validation study.
|
||||
|
||||
2. medRxiv preprint (November 2025): Complex medical subspecialty scenarios. OE achieved 24% accuracy for relevant answers (vs. 2-10% for other LLMs on open-ended questions). Note: USMLE-type multiple choice shows 100% — open-ended clinical scenarios show 24%.
|
||||
|
||||
*Registered but unpublished:*
|
||||
3. NCT07199231 — "OpenEvidence Safety and Comparative Efficacy of Four LLMs in Clinical Practice"
|
||||
- Design: Prospective study, medicine/psychiatry residents at community health centers
|
||||
- Comparators: OE vs. ChatGPT vs. Claude vs. Gemini
|
||||
- Primary outcome: whether OE leads to "clinically appropriate decisions" in actual practice
|
||||
- Gold standard comparison: PubMed + UpToDate
|
||||
- Duration: 6-month data collection period
|
||||
- Status: Data collection underway (as of March 2026); results not yet published
|
||||
- This is the first prospective outcomes trial for any major clinical AI platform
|
||||
|
||||
**Key competitive/safety context:**
|
||||
- Sutter Health partnership: OE integrated into clinical workflows at Sutter Health system
|
||||
- "Answered with Evidence" framework (arXiv preprint, July 2025): OE-developed framework for evaluating whether LLM answers are evidence-grounded
|
||||
- MedCity News: "Thunderstruck By OpenEvidence's $12B Valuation? Don't Be." — positive industry reception
|
||||
- STAT News: "OpenEvidence raises $250 million, doubling its valuation" — covered as clinical AI milestone
|
||||
|
||||
**Sources:**
|
||||
- BusinessWire: Series D press release (primary)
|
||||
- MobiHealthNews: "$12B valuation doubles" report
|
||||
- STAT News: Funding analysis
|
||||
- PubMed 40238861: Primary care clinical decision-making study
|
||||
- ClinicalTrials.gov NCT07199231: Prospective safety trial registration
|
||||
- PubMed PMC12951846: OpenEvidence PMC article
|
||||
- arXiv 2507.02975: "Answered with Evidence" preprint
|
||||
|
||||
## Agent Notes
|
||||
|
||||
**Why this matters:** OpenEvidence is the largest real-world test of clinical AI at scale in history. At 30M+ monthly physician consultations with near-zero outcomes evidence, it represents either the most significant health improvement in clinical decision-making (if safe and effective) or the most widespread unmonitored clinical AI deployment in history (if there are systematic safety issues). The $12B valuation at 1,803% YoY growth makes this a significant health AI investment signal.
|
||||
|
||||
**What surprised me:** Two things in opposite directions.
|
||||
|
||||
UNEXPECTED-POSITIVE: The PMC finding ("reinforces plans rather than changing them") is actually a WEAKER safety signal than previous analysis assumed. If OE is mostly confirming what physicians were already planning, it's not introducing new decisions that could be wrong — it's adding evidence support to existing clinical judgment. The automation-bias deskilling risk is predicated on physicians CHANGING behavior based on AI recommendations. If they're not changing behavior, the deskilling mechanism may be weaker for OE specifically.
|
||||
|
||||
UNEXPECTED-CONCERNING: The 3.4x valuation jump in 3 months ($3.5B → $12B) is extraordinary even by AI standards. The company is now projecting "medical superintelligence" as its goal. The $12B/30M monthly consultations math implies ~$400 in implied value per monthly user. The PMC finding ("minimal clinical decision-making impact") and the valuation are in extreme tension.
|
||||
|
||||
**What I expected but didn't find:** An OE-initiated outcomes study. At $150M ARR and $700M in total funding, OE has resources to fund a large-scale outcomes trial. The fact that the only prospective trial (NCT07199231) appears to be researcher-initiated (not OE-sponsored) — and is based at a community health center with residents, not OE-sponsored at scale — suggests OE has not prioritized outcomes evidence. The company is scaling without commissioning the evidence to validate safety.
|
||||
|
||||
**KB connections:**
|
||||
- Primary: [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]] — PMC finding COMPLICATES this: if OE reinforces rather than changes, the deskilling mechanism requires revision
|
||||
- Secondary: [[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]] — the PMC finding is consistent with this
|
||||
- Cross-domain (Theseus): The $12B valuation + zero outcomes evidence + "medical superintelligence" framing is a case study in AI deployment without safety validation. Theseus should know about NCT07199231 — it's one of the only prospective safety trials for clinical AI at scale.
|
||||
|
||||
**Extraction hints:**
|
||||
- Primary claim: OpenEvidence's only published peer-reviewed clinical validation (PMC, 2025) found OE "reinforced existing plans rather than changing them" despite high physician satisfaction — suggesting the platform's primary function is confidence reinforcement, not decision improvement
|
||||
- Secondary claim: OpenEvidence's $12B valuation ($3.5B → $12B in 3 months) and "medical superintelligence" positioning reflect investor expectations of disruption that are in direct tension with the published clinical evidence of minimal decision-making impact
|
||||
- Third claim candidate: NCT07199231 as the first prospective safety trial for any major clinical AI platform — methodology matters for the KB's clinical AI safety claims
|
||||
- Flag for Theseus: the "reinforces plans" finding could be a Goodhart's Law failure mode — physicians are using OE as validation of decisions they've already made, creating overconfidence at scale rather than better decisions
|
||||
|
||||
**Context:** Multiple sources aggregated for this archive. The January 21 Series D press release is the anchor event; the PMC study and NCT registration provide the evidence context.
|
||||
|
||||
## Curator Notes (structured handoff for extractor)
|
||||
|
||||
PRIMARY CONNECTION: [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]
|
||||
|
||||
WHY ARCHIVED: The PMC finding ("reinforces plans") provides the first direct clinical evidence about OE's mechanism — and it partially CHALLENGES the deskilling KB claim by suggesting OE isn't changing decisions, just confirming them. This needs to be in the KB to update the clinical AI safety picture.
|
||||
|
||||
EXTRACTION HINT: The extractor should focus on: (1) the PMC "reinforces plans" finding and its implications for the deskilling mechanism; (2) the $12B valuation vs. zero outcomes evidence asymmetry as a documented KB tension; (3) NCT07199231 as the methodology reference for future outcomes data.
|
||||
|
|
@ -0,0 +1,76 @@
|
|||
---
|
||||
type: source
|
||||
title: "Semaglutide US Import Wall Holds But Gray Market Pressure Builds as India Generics Launch"
|
||||
author: "FDA / Doctronic / Medical News Today / FDA"
|
||||
url: https://www.doctronic.ai/blog/compounded-semaglutide/
|
||||
date: 2026-03-21
|
||||
domain: health
|
||||
secondary_domains: []
|
||||
format: article
|
||||
status: processed
|
||||
priority: medium
|
||||
tags: [glp1, semaglutide, us-importation, compounding-pharmacy, fda, gray-market, patent-wall, personal-import]
|
||||
---
|
||||
|
||||
## Content
|
||||
|
||||
**Current US legal framework for semaglutide (as of March 2026):**
|
||||
|
||||
1. **Compounded semaglutide is now illegal for standard doses.** The FDA removed injectable semaglutide from the drug shortage list on February 21, 2025. This closed the compounding exception — during the shortage period (2023-2025), compounding pharmacies legally produced semaglutide. That exception ended with the shortage resolution. The compounding channel that provided quasi-legal affordable access in 2024 is now definitively closed.
|
||||
|
||||
2. **Personal importation is technically illegal.** To legally sell semaglutide in the US, a manufacturer must obtain FDA approval and comply with strict import, manufacturing, and labeling requirements. Indian generic semaglutide does not have FDA approval and cannot legally be sold, prescribed, or administered in the US regardless of cost or claimed equivalence.
|
||||
|
||||
3. **FDA established import alert 66-80** to screen non-compliant GLP-1 active pharmaceutical ingredients. This does not apply to GLP-1 API from manufacturers in compliance with FDA manufacturing standards — allowing legal API importation for compliant manufacturers, not consumer-level drug importation.
|
||||
|
||||
4. **Novo Nordisk's higher-dose Wegovy** received FDA approval on March 20, 2026 — the same day India patents expired. Differentiation strategy: move up the dose ladder while generics occupy lower doses.
|
||||
|
||||
**Gray market risk (FDA explicit warning):**
|
||||
|
||||
The FDA explicitly stated: "some overseas companies will likely begin marketing semaglutide to US consumers, taking advantage of confusion around the FDA's personal importation policy, and patients might assume personal importation is permitted, and some will act on it."
|
||||
|
||||
- "PeptideDeck" and similar gray-market supplier sites are already marketing to US consumers
|
||||
- The price arbitrage: Natco generic at ~$15/month vs. Wegovy at ~$1,200/month US
|
||||
- FDA personal importation enforcement is discretionary and capacity-constrained
|
||||
- Gray market volume will be visible by Q3 2026
|
||||
|
||||
**US patent timeline (the wall):**
|
||||
- Ozempic (injectable semaglutide): US patent 2031-2033
|
||||
- Wegovy (injectable semaglutide, obesity indication): similar timeline
|
||||
- Rybelsus (oral semaglutide): separate patent timeline, potentially different
|
||||
- Until these patents expire, the US cannot have legally approved generic semaglutide
|
||||
|
||||
**Sources:**
|
||||
- Doctronic.ai: "Compounded Semaglutide: What the FDA Says in 2026"
|
||||
- Medical News Today: "Did the FDA ban compounded semaglutide?"
|
||||
- FDA.gov: Shortage resolution notice
|
||||
- Burr & Forman: Legal analysis of compounding restrictions
|
||||
- FDA.gov: Import alert 66-80 guidance
|
||||
- CEN (American Chemical Society): "Nozempic? A look at what will happen when GLP-1 drugs go off patent" (December 2025)
|
||||
|
||||
## Agent Notes
|
||||
|
||||
**Why this matters:** This source documents the WALL that the India generic launch faces in the US market. The compounding channel (2023-2025's quasi-legal access pathway) is closed. The legal importation pathway doesn't exist. But the gray market pressure is building, and the FDA explicitly acknowledges it will happen. This is the critical missing piece for the GLP-1 KB claim: the US will have price compression, but through gray market channels, not legal ones — and the timeline is more uncertain.
|
||||
|
||||
**What surprised me:** The FDA's explicit acknowledgment that "patients will assume personal importation is permitted, and some will act on it" is unusual candor. The agency is essentially pre-announcing that it expects a gray market to develop and is warning — not promising — to enforce against it. This is very different from the FDA's language around most import issues.
|
||||
|
||||
**What I expected but didn't find:** A clear FDA policy statement on personal importation enforcement priorities. The FDA's personal importation guidance is vague ("generally not pursued if for personal use, limited quantities"), which creates the confusion the FDA itself is warning about. No clarity on enforcement threshold.
|
||||
|
||||
**KB connections:**
|
||||
- Primary: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — the US remains "inflationary" through legal channels through 2031-2033, but gray market pressure will be visible before that
|
||||
- Secondary: the compounding pharmacy closure connects to the broader clinical AI reimbursement story — FDA policy shapes what's accessible
|
||||
- Cross-domain: Rio should track the compounding pharmacy industry consolidation/shutdown that follows semaglutide losing its primary revenue stream
|
||||
|
||||
**Extraction hints:**
|
||||
- Primary claim: FDA removal of semaglutide from shortage list (February 2025) closed the compounding access channel that provided quasi-legal affordable access during 2023-2025, creating a legal vacuum where only Novo Nordisk's branded products are legally accessible in the US through 2031-2033
|
||||
- Secondary claim: gray market semaglutide importation from India to the US will build despite illegality because the $1,185/month price arbitrage ($1,200 Wegovy vs $15 Natco) exceeds FDA enforcement capacity
|
||||
- Don't extract the "wall" framing as a claim — it's contextual analysis, not a specific testable assertion
|
||||
|
||||
**Context:** This source aggregates FDA policy documents and legal analysis. The key dates: February 2025 (shortage resolved/compounding closed), March 2026 (India patents expire/gray market builds). These are the two poles of the US access story.
|
||||
|
||||
## Curator Notes (structured handoff for extractor)
|
||||
|
||||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
|
||||
WHY ARCHIVED: This documents the mechanism that keeps the US "inflationary" claim partially true for legal channels while explaining why the claim is being eroded by gray market channels. The compounding closure and import wall are the specific regulatory barriers that maintain the US/international price gap.
|
||||
|
||||
EXTRACTION HINT: The extractor should focus on: (1) February 2025 compounding closure — the specific date the legal access pathway closed; (2) FDA's explicit gray market warning — this is an admission that price arbitrage will produce illegal importation at scale; (3) the 2031-2033 patent expiry as the only legal resolution date for the US market.
|
||||
|
|
@ -0,0 +1,34 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "openevidence-reinforces-existing-clinical-plans-rather-than-changing-decisions-suggesting-confidence-support-not-decision-improvement.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor",
|
||||
"opsec_internal_deal_terms"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "nct07199231-is-first-prospective-safety-trial-for-major-clinical-ai-platform-establishing-outcomes-methodology-precedent.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"openevidence-reinforces-existing-clinical-plans-rather-than-changing-decisions-suggesting-confidence-support-not-decision-improvement.md:set_created:2026-03-21",
|
||||
"nct07199231-is-first-prospective-safety-trial-for-major-clinical-ai-platform-establishing-outcomes-methodology-precedent.md:set_created:2026-03-21"
|
||||
],
|
||||
"rejections": [
|
||||
"openevidence-reinforces-existing-clinical-plans-rather-than-changing-decisions-suggesting-confidence-support-not-decision-improvement.md:missing_attribution_extractor",
|
||||
"openevidence-reinforces-existing-clinical-plans-rather-than-changing-decisions-suggesting-confidence-support-not-decision-improvement.md:opsec_internal_deal_terms",
|
||||
"nct07199231-is-first-prospective-safety-trial-for-major-clinical-ai-platform-establishing-outcomes-methodology-precedent.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-21"
|
||||
}
|
||||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "fda-compounding-pharmacy-closure-february-2025-eliminated-quasi-legal-affordable-glp1-access.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "gray-market-semaglutide-importation-will-build-despite-illegality-due-to-1185-monthly-arbitrage.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"fda-compounding-pharmacy-closure-february-2025-eliminated-quasi-legal-affordable-glp1-access.md:set_created:2026-03-21",
|
||||
"gray-market-semaglutide-importation-will-build-despite-illegality-due-to-1185-monthly-arbitrage.md:set_created:2026-03-21"
|
||||
],
|
||||
"rejections": [
|
||||
"fda-compounding-pharmacy-closure-february-2025-eliminated-quasi-legal-affordable-glp1-access.md:missing_attribution_extractor",
|
||||
"gray-market-semaglutide-importation-will-build-despite-illegality-due-to-1185-monthly-arbitrage.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-21"
|
||||
}
|
||||
|
|
@ -7,10 +7,14 @@ date: 2026-01-21
|
|||
domain: health
|
||||
secondary_domains: [ai-alignment]
|
||||
format: article
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [openevidence, clinical-ai, outcomes-gap, deskilling, automation-bias, valuation, nct07199231, verification-bandwidth, medical-superintelligence]
|
||||
flagged_for_theseus: ["$12B clinical AI valuation with zero outcomes evidence — directly relevant to AI safety at scale; prospective trial NCT07199231 is the first real-world test of clinical AI safety methodology; 'reinforces plans' finding from PMC study could be a Goodhart's Law failure mode"]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-21
|
||||
enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -96,3 +100,16 @@ PRIMARY CONNECTION: [[human-in-the-loop clinical AI degrades to worse-than-AI-al
|
|||
WHY ARCHIVED: The PMC finding ("reinforces plans") provides the first direct clinical evidence about OE's mechanism — and it partially CHALLENGES the deskilling KB claim by suggesting OE isn't changing decisions, just confirming them. This needs to be in the KB to update the clinical AI safety picture.
|
||||
|
||||
EXTRACTION HINT: The extractor should focus on: (1) the PMC "reinforces plans" finding and its implications for the deskilling mechanism; (2) the $12B valuation vs. zero outcomes evidence asymmetry as a documented KB tension; (3) NCT07199231 as the methodology reference for future outcomes data.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- OpenEvidence Series D: $250M at $12B valuation, January 21, 2026
|
||||
- OpenEvidence previous valuation: $3.5B (October 2025 Series C)
|
||||
- OpenEvidence total funding: ~$700M
|
||||
- OpenEvidence 2025 revenue: $150M ARR, up 1,803% YoY from $7.9M in 2024
|
||||
- OpenEvidence gross margins: ~90%
|
||||
- OpenEvidence usage: 18M monthly consultations (December 2025) → 30M+ monthly (March 2026)
|
||||
- OpenEvidence milestone: 1 million consultations in a single day (March 10, 2026)
|
||||
- OpenEvidence reach: 10,000+ hospitals, 40%+ of US physicians use daily
|
||||
- NCT07199231 status: Data collection underway as of March 2026, results unpublished
|
||||
- NCT07199231 design: 6-month prospective study with medicine/psychiatry residents at community health centers
|
||||
|
|
|
|||
|
|
@ -7,9 +7,13 @@ date: 2026-03-21
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: article
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [glp1, semaglutide, us-importation, compounding-pharmacy, fda, gray-market, patent-wall, personal-import]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-21
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -74,3 +78,14 @@ PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic catego
|
|||
WHY ARCHIVED: This documents the mechanism that keeps the US "inflationary" claim partially true for legal channels while explaining why the claim is being eroded by gray market channels. The compounding closure and import wall are the specific regulatory barriers that maintain the US/international price gap.
|
||||
|
||||
EXTRACTION HINT: The extractor should focus on: (1) February 2025 compounding closure — the specific date the legal access pathway closed; (2) FDA's explicit gray market warning — this is an admission that price arbitrage will produce illegal importation at scale; (3) the 2031-2033 patent expiry as the only legal resolution date for the US market.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- FDA removed injectable semaglutide from drug shortage list on February 21, 2025
|
||||
- India semaglutide patents expired March 2026
|
||||
- Novo Nordisk's higher-dose Wegovy received FDA approval March 20, 2026
|
||||
- FDA established import alert 66-80 to screen non-compliant GLP-1 APIs
|
||||
- Natco generic semaglutide costs approximately $15/month
|
||||
- Wegovy costs approximately $1,200/month in the US
|
||||
- US patent protection for Ozempic extends to 2031-2033
|
||||
- Compounding pharmacies legally produced semaglutide during 2023-2025 shortage period
|
||||
|
|
|
|||
Loading…
Reference in a new issue